Prevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
Drug sensitivity to, in particular to favipiravir, may vary among representatives of different ethnic groups. Studies have previously shown that carrying certain variants of the AOX1 and CYP1A2 genes may be associated with an increased incidence of adverse reactions with patients having COVID-19 and...
Saved in:
| Main Authors: | A. T. Leinsoo, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, A. V. Kryukov, S. N. Mammaev, Zh. A. Sozaeva, M. S.-Kh. Sozaeva, K. A. Akmalova, L. Z. Bolieva, A. I. Dobroselskaya, M. L. Maksimov, K. B. Mirzaev, D. A. Sychev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2025-07-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/1670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01) -
Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2
by: N. P. Denisenko, et al.
Published: (2022-02-01) -
Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01) -
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
by: Abdullah Sayiner, et al.
Published: (2022-03-01) -
STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
by: L. A. Balykova, et al.
Published: (2021-12-01)